首页 | 本学科首页   官方微博 | 高级检索  
检索        

RNA干扰Bcl-2基因表达对人胆管癌细胞及胆囊癌细胞株裸鼠移植瘤生长的抑制
引用本文:潘晓涛,马龙安,李纯义,王一凡.RNA干扰Bcl-2基因表达对人胆管癌细胞及胆囊癌细胞株裸鼠移植瘤生长的抑制[J].现代肿瘤医学,2012,20(1):31-34.
作者姓名:潘晓涛  马龙安  李纯义  王一凡
作者单位:陕西省肿瘤医院,陕西,西安,710061
基金项目:陕西省自然科学基金资助项目(No.2003C2 47)
摘    要:目的:探讨Bcl-2基因的小干扰RNA(siRNA)真核表达载体干扰Bcl-2基因表达对人胆管癌细胞QBC939、胆囊癌细胞GBC-SD裸鼠体内移植瘤生长的抑制作用.方法:分别制作人胆管癌细胞QBC939、胆囊癌细胞GBC-SD细胞株移植瘤模型,随机分为3组,pSilencerTM-EGFP sh515组(实验组)、pSilencerTM-EGFP shCon组(空载体阴性对照组)和对照组.实验组用Bcl-2基因的小干扰RNA(siRNA)真核表达载体多点注射于移植瘤周围,空载体阴性对照组用空载体多点注射于移植瘤周围,对照组不作处理,观察其生长情况,计算肿瘤生长体积、生长率.6周后,处死裸鼠,剥离瘤体组织进行称重,并采用免疫组化检测Bcl-2蛋白的表达.结果:成功建立裸鼠人胆管癌细胞QBC939,胆囊癌GBC-SD细胞的动物模型.胆管癌细胞实验组、空载体阴性对照组、对照组瘤体平均体积(mm3)分别为:801.776±59.6,1383.980±78.2,1490.235±89.0.瘤体平均瘤体重量(g)为:0.90±0.11,1.49±0.31,1.63±0.22.平均生长率为:20.558%,35.587%,38.211%.人胆囊癌细胞实验组、空载体阴性对照组、对照组瘤体平均体积(mm3)分别为:729.736±66.6,1493.162±98.9,1548.668±101.0.瘤体平均瘤体重量(g)为:0.82±0.10,1.68±0.21,1.90±0.25.平均生长率为:18.711%,38.286%,39.709%.两组实验组分别和空载体阴性对照组、对照组比较有统计学意义(P<0.05),空载体阴性对照组和对照组比较无统计学意义(P>0.05).结论:针对Bcl-2基因siRNA真核表达载体通过局部多点注射于移植瘤周围可以有效降低Bcl-2基因的表达,该基因沉默后肿瘤细胞增殖受到抑制,体内瘤体生长减慢.

关 键 词:胆管癌  胆囊癌  Bcl-2基因  RNA干扰  移植瘤  基因治疗

RNA interference mediated Bcl-2 gene silence inhibits growth of human cholangiocarcinoma and gallbladder carcinoma xenograft in nude mice
PAN Xiaotao,MA Longan,LI Chunyi,WANG Yifan.RNA interference mediated Bcl-2 gene silence inhibits growth of human cholangiocarcinoma and gallbladder carcinoma xenograft in nude mice[J].Journal of Modern Oncology,2012,20(1):31-34.
Authors:PAN Xiaotao  MA Longan  LI Chunyi  WANG Yifan
Institution:Shaanxi Tumour Hospital,Shaanxi Xi’an 710061,China.
Abstract:Objective:Investigating RNA interference mediated Bcl-2 gene silence can inhibit growth of the cholangiocarcinoma and gallbladder carcinoma xenograft in nude mice.Methods: The animal models of human cholangiocarcinoma and Gallbladder carcinoma in nude mice body were set up.The nude mice were randomly divided into three groups: pSilencerTM-EGFP sh515,pSilencerTM-EGFP shCon,control group.After the formation of tumor knot,siRNA expressing plasmids pSilencerTM-EGFP sh515 and pSilencerTM-EGFP shCon were injected into the knots of pSilencerTM-EGFP sh515 group and pSilencerTM-EGFP shCon group.The volumes of the tumors were measured and the tumor growth rates were calculated.All mice were sacrificed after 6 weeks.The distribution of Bcl-2 in the tumors was detected by immunohistochemistry.Results: The nude mouse model of human cholangiocarcinoma and gallbladder cancer xenograft tumor was constructed successfully.The cholangiocarcinoma average tumor volumes(mm3)in pSilencerTM-EGFP sh515 group,pSilencerTM-EGFP shCon group,control group was 801.776±59.6,1383.980±78.2,1490.235±89.0,and the average tumor weight(g) was 0.90±0.11,1.49±0.31,1.63±0.22,and the average growth rates was 20.558%,35.587%,38.211%.The gallbladder cancer average tumor volumes(mm3)in pSilencerTM-EGFP sh515 group,pSilencerTM-EGFP shCon group,control group were 729.736±66.6,1493.162±98.9,1548.668±101.0,and the average tumor weight(g) was 0.82±0.10,1.68±0.21,1.90±0.25,and the average growth rates were 18.711%,38.286%,39.709%.The average tumor volume,weight and growth rates of pSilencerTM-EGFP sh515 group was significantly smaller than that of pSilencerTM-EGFP shCon group and control group(P<0.05),and there was no significant difference between pSilencerTM-EGFP shCon group and control group(P>0.05).Conclusion: By local injection,siRNA vector can effectively degrade the expressive level of Bcl-2 gene.After silence of Bcl-2 gene,the xenograft growth rate decreased.
Keywords:gallbladder carcinoma  Bcl-2 gene  RNA interference  xenograft  gene therapy
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号